Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
Lisata Therapeutics
Acquired Company
Marea Therapeutics
Description
Lisata Therapeutics has successfully acquired Marea Therapeutics, enhancing its clinical drug development pipeline. The acquisition aims to advance lead product candidate MAR001, targeting severe hypertriglyceridemia. This move is part of Lisata's strategic growth and commitment to innovative treatments. The company continues to push forward its clinical programs with new leadership and expertise.
Fundz sees it the moment Lisata Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Marea Therapeutics?
Marea Therapeutics was acquired by Lisata Therapeutics, based in Cincinnati. The deal was reported on October 15, 2026. Lisata Therapeutics Inc (NASDAQ:LSTA) is a pharmaceutical company that is partnering with the University of Cincinnati to investigate endometriosis therapy. Lisata Therapeutics is publicly traded (LSTA) and operates in Biotechnology.
When did Lisata Therapeutics acquire Marea Therapeutics?
Lisata Therapeutics's acquisition of Marea Therapeutics was reported on October 15, 2026. Lisata Therapeutics has successfully acquired Marea Therapeutics, enhancing its clinical drug development pipeline. The acquisition aims to advance lead product candidate MAR001, targeting severe hypertriglyceridemia. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Marea Therapeutics do?
Marea Therapeutics is a clinical-stage biotechnology company focused on developing a new generation of medicines for cardiometabolic diseases. It is privately held, operating in Biotechnology, and is based in San Francisco.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.